A pathophysiology diagram illustrating the integrated role of extracellular vesicles (EVs) in the pathogenesis of preeclampsia. The flowchart identifies two primary triggers: 'Maternal Risk Factors' (including age, obesity, diabetes, and hypertension) and 'Placental Abnormalities' (such as hypoxia, ischemia-reperfusion injury, and syncytiotrophoblast-derived EV release). These triggers lead to 'Systemic maternal cell activation,' which is depicted as a central mechanism involving three main pathways: 1) Endothelial activation, 2) Leukocyte activation (neutrophils, monocytes, and lymphocytes), and 3) Platelet activation. Each cell type is shown releasing vesicles that mediate cross-talk between systems. The diagram shows how these cellular activations result in three downstream clinical consequences: vascular dysfunction, immune modulation/inflammation, and increased thrombotic propensity. These pathological processes collectively culminate in the clinical manifestation of Preeclampsia. This diagram serves as an educational summary of how maternal-placental interactions through EVs drive systemic inflammation and vascular damage in pregnancy-induced hypertension disorders.

This pathophysiology diagram illustrates the immunological mechanisms underlying three distinct maternal states: Normal Pregnancy, Early-Onset Preeclampsia, and Late-Onset Preeclampsia. The flowchart begins with the process of implantation and spiral artery remodeling. In a normal pregnancy, macrophages, dendritic cells, NK cells, and T helper cells balance inflammatory and angiogenic signals to promote proper vascular remodeling and anti-inflammatory maternal T cell responses. Early-onset preeclampsia is characterized by the disruption of spiral artery formation by inflammatory immune cells, leading to placental hypoxia, trophoblast death, and polarization toward inflammatory T cells. Late-onset preeclampsia follows a normal initial vascular remodeling phase, but subsequently enters a pathological state when placental needs exceed uterine perfusion capacity. Both preeclampsia pathways converge on systemic chronic inflammation, driven by inflammatory cytokines and mediators like sflt-1 and AT1-AA. These factors result in placental, vascular, and renal dysfunction, culminating in gestational hypertension. The diagram highlights that the inflammatory environment persists into the postpartum period, increasing future pregnancy risks.

Summary : This timeline chart illustrates the typical onset and duration of four major liver-related complications during pregnancy: Hyperemesis Gravidarum, Intrahepatic Cholestasis of Pregnancy, Preeclampsia/Eclampsia/HELLP, and Acute Fatty Liver of Pregnancy, mapped across the trimesters and into the post-partum period. timeline chart: Scope & Reference : • Time axis spans from 1st Trimester (0–12 weeks), 2nd Trimester (13–28 weeks), 3rd Trimester (29–40 weeks), to Post-Partum (delivery to days). • Each complication is represented by a horizontal arrow indicating its typical period of occurrence. Keys & Annotations : • Hyperemesis Gravidarum: Arrow starts in 1st Trimester and extends through 2nd and 3rd Trimesters. • Intrahepatic Cholestasis of Pregnancy: Arrow begins in 2nd Trimester and continues through 3rd Trimester, ending at delivery. • Preeclampsia/Eclampsia/HELLP: Arrow starts in 3rd Trimester and ends at delivery. • Acute Fatty Liver of Pregnancy: Arrow starts in 3rd Trimester and extends into the Post-Partum period. Ordering : • Arrows are stacked vertically, each labeled with the condition name. • The timeline is segmented by vertical lines marking the start of each trimester and the post-partum period. Analysis : • Hyperemesis Gravidarum is the earliest and longest-lasting condition, potentially spanning all trimesters. • Intrahepatic Cholestasis of Pregnancy and Preeclampsia/Eclampsia/HELLP are concentrated in later trimesters, with the latter two peaking near delivery. • Acute Fatty Liver of Pregnancy is the latest onset, often extending into the immediate post-partum period. • The chart visually distinguishes the temporal risk windows for each condition, aiding clinical awareness of when to monitor for specific complications.